Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Adocia brings in €14mm through its Series B round

Executive Summary

Adocia SAS (regenerative medicine) has raised €14mm ($20.1mm) through the closing of its Series B venture round. New backers InnoBio (€6mm) and SHAM (€2mm) were joined by current shareholders including Adocia founders. The money will be used to continue clinical development of its fast-acting human insulin and BioChaperone growth factor compounds for wound healing and bone repair.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies